The KEYS trial evaluated which treatment modification in locally advanced cervical cancer?
- A Replacement of cisplatin with carboplatin in concurrent chemoradiation
- B Neoadjuvant chemotherapy before radical hysterectomy vs. chemoradiation
- C Addition of pembrolizumab to concurrent chemoradiation ✓
- D Extended-field radiation vs. pelvic radiation alone
Correct answer: C. Addition of pembrolizumab to concurrent chemoradiation
Explanation
The KEYNOTE-A18 (KEYS) trial evaluated the addition of pembrolizumab (anti-PD-1 checkpoint inhibitor) to concurrent chemoradiation in locally advanced cervical cancer (FIGO 2014 Stage IIB–IVA). Results showed significant improvement in progression-free survival, leading to FDA approval of this combination. Carboplatin substitution has been studied in OUTBACK trial. Neoadjuvant chemotherapy was evaluated in other trials (EORTC 55994).
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.